Ultime notizie per AIM ImmunoTech (AMEX:AIM) Azioni

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech Inc

Aimfinity Investment Corp I

Altra Industrial Motion Corp Com

Ainos Inc

Aimia Inc

AIMRITE HOLDINGS CORP by Aimrite Holdings Corporation

Aimrite Holdings Corp

AI / ML INNOVATIONS INC by AI / ML Innovations Inc.

AI/ML Innovations Inc

Immersed Inc

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic Cancer
Warns Shareholders of Its Belief that the Activist Group and Its Nominees Have a Self-Interested Agenda and Could Put AIM's Clinical Progress at Risk
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group
Shareholders Can View and Download the Presentation <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=Here&amp;index=1&amp;md5=aebd9987f2d8525d889b11917beb3e81">Here</a>
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today issued a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FAIM%2BInvestor%2BPresentation%2B%28November%2B2024%29.pdf&amp;esheet=54157417&amp;newsitemid=20241125176144&amp;lan=en-US&amp;anchor=presentation&amp;index=2&amp;md5=f3ad08194b4528269f1b5432d10f7266">presentation</a> in connection with its upcoming 2024 Annual Meeting of Stockholders the ("Annual Meeting"), presently scheduled for December 17, 2024.
Highlights of the presentation include the following:
<ul>
<li>AIM is executing on its strategy to create long-term value for patients and shareholders by driving clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space.</li>
<li>AIM's clinical pipeline has significant momentum and is laying the groundwork for commercialization opportunities by delivering exciting data across clinical trials, including in two ongoing studies with AstraZeneca and Merck. These commercialization opportunities are what can drive substantial value creation.</li>
<li>If elected, the Activist Group intends to seek over $5 million from AIM to pay for its previous takeover attempts and litigation against the Company that the Activist Group lost, in addition to any expenses incurred in connection with its solicitation for this year's Annual Meeting. The Activist Group disclosed that it does notintend to put this personal reimbursement to a shareholder vote.</li>
<li>Despite AIM's best attempts at a constructive settlement that would put two of the Activist Group's nominees on the Board, the Activist Group has continued to insist it receive upwards of $8 million to make all litigants whole in connection with certain litigation as part of any resolution – this represents more than 50% of AIM's current market capitalization.</li>
<li>The Activist Group has indicated it would likely appoint Robert Chioini as interim CEO while the Board runs a succession process should its nominees gain control of the Board. Mr. Chioini was fired as CEO of Rockwell Medical in 2018 because of his "sustained mismanagement" of the company and "blatant disregard for shareholder concerns," according to a Rockwell Medical spokesperson.1 Following his termination, Mr. Chioini "refuse[d] to accept the decision" and, without authorization, filed a Current Report on Form 8-K on the company's behalf "making various assertions regarding the five independent directors who voted in favor of Mr. Chioini's removal."2This behavior indicates, in our view, that Mr. Chioini is unfit to serve as a public company director – let alone CEO.</li>
</ul>

News

Management

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Insider Trades

SEC Form 4 Filing Shows AIM ImmunoTech CEO And Director Thomas K. Equels Purchases 85,000 Shares At An Average Price Of $0.20

AIM ImmunoTech Form4 Filing Shows CEO And President Thomas K Equels Bought 60,110 Shares At An Average Price Of $0.18/Share

General

AIM ImmunoTech shares are trading higher after the company announced the publication of Phase 1 data from its Roswell Park study on Ampligen in early-stage triple-negative breast cancer.

Biotech

AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer

<a href="https://www.roswellpark.org/newsroom/202411-roswell-park-clinical-trial-points-toward-promising-new-therapy-most-aggressive" title="https://www.roswellpark.org/newsroom/202411-roswell-park-clinical-trial-points-toward-promising-new-therapy-most-aggressive">https://www.roswellpark.org/newsroom/202411-roswell-park-clinical-trial-points-toward-promising-new-therapy-most-aggressive</a>

Roswell Park's Phase 1 Trial Results For Triple-Negative Breast Cancer, With 66% Achieving Complete Or Near-Complete Remission And No Immune-Related Adverse Events; Findings Published In Journal For ImmunoTherapy Of Cancer

AIM ImmunoTech shares are trading higher after the company reported better-than-expected Q3 EPS results.

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 50 percent. The company reported quarterly sales of $35.00 thousand which missed the analyst consensus estimate of $67.50 thousand by 48.15 percent. This is a 23.91 percent decrease over sales of $46.00 thousand the same period last year.

Earnings

AIM ImmunoTech Q3 2024 GAAP EPS $(0.06) Beats $(0.12) Estimate, Sales $35.00K Miss $67.50K Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $72.08 million. 
• Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) is projected to report quarterly loss at $0.54 per share on revenue of $16.50 million. 
• Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) is projected to report quarterly loss at $0.13 per share on revenue of $9.90 million. 
• Aegon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEG#NYSE">AEG</a>) is projected to report earnings for its third quarter. 
• Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) is expected to report earnings for its third quarter. 
• WiSA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) is likely to report quarterly loss at $0.68 per share on revenue of $1.00 million. 
• AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is likely to report quarterly loss at $0.10 per share on revenue of $20 thousand. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $87.84 million. 
• RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $105.08 million. 
• Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is projected to report quarterly earnings at $2.10 per share on revenue of $33.95 billion. 
• Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $746.54 million. 
<h3>Companies Reporting After The Bell</h3>
• Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) is likely to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BABA

BPTH

DGHI

NEXN

NGNE

SGML

TRIB

WISA

Earnings Scheduled For November 15, 2024

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) will release its quarterly earnings report on Friday, 2024-11-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate AIM ImmunoTech to report an earnings per share (EPS) of $-0.10.
The market awaits AIM ImmunoTech's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.09, leading to a 5.88% increase in the share price the following trading session.
Here's a look at AIM ImmunoTech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.12</td>
<td>-0.26</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>3.0%</td>
<td>6.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731592849_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of AIM ImmunoTech were trading at $0.242 as of November 13. Over the last 52-week period, shares are down 46.1%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AIM/earnings">To track all earnings releases for AIM ImmunoTech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into AIM ImmunoTech's Upcoming Earnings

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-08-14. Here's what investors need to know before the announcement.
Analysts estimate that AIM ImmunoTech will report an earnings per share (EPS) of $-0.12. 
Anticipation surrounds AIM ImmunoTech's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.01, which was followed by a 3.33% increase in the share price the next day.
Here's a look at AIM ImmunoTech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.12</td>
<td>-0.26</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>3.0%</td>
<td>6.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731002593_0.png" alt="eps graph" />
<h3>Market Performance of AIM ImmunoTech's Stock</h3>
Shares of AIM ImmunoTech were trading at $0.2498 as of November 06. Over the last 52-week period, shares are down 40.31%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/AIM/earnings">To track all earnings releases for AIM ImmunoTech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring AIM ImmunoTech's Earnings Expectations

Warns Shareholders that Activist Group's Self-Interested Agenda Could Disrupt AIM's Momentum and Destroy Chances for Near-Term Value Creation
Expresses Excitement About Encouraging Progress of Clinical Trials for Ampligen in High-Value Indications Including Pancreatic Cancer
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group
Visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SafeguardAIM.com&amp;esheet=54146383&amp;newsitemid=20241104047141&amp;lan=en-US&amp;anchor=www.SafeguardAIM.com&amp;index=1&amp;md5=26a36f092f0e80e1a5a9de1343eb006a">www.SafeguardAIM.com</a> for More Information
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) (the "Company") today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming 2024 Annual Meeting of Stockholders, scheduled for December 17, 2024. The Company also mailed a letter to shareholders.

AIM ImmunoTech Files Definitive Proxy Statement And Sends Letter To Shareholders; Warns Shareholders That Activist Group's Self-Interested Agenda Could Disrupt Aim's Momentum And Destroy Chances For Near-Term Value Creation

Maxim Group analyst Jason McCarthy maintains AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) with a Buy and lowers the price target from $2 to $1.

Price Target

Analyst Ratings

Maxim Group Maintains Buy on AIM ImmunoTech, Lowers Price Target to $1

<h3>Gainers</h3>
<ul>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 51.3% to $0.76 during Thursday's after-market session. The company's market cap stands at $116.9 million. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares increased by 11.57% to $0.27. The market value of their outstanding shares is at $15.4 million. </li>
<li>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) shares rose 7.63% to $19.5. The company's market cap stands at $1.3 billion. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) stock moved upwards by 7.04% to $5.62. The company's market cap stands at $132.9 million. </li>
<li>Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) shares increased by 4.99% to $11.77. The company's market cap stands at $8.7 billion. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares increased by 4.63% to $1.58. The market value of their outstanding shares is at $133.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock fell 8.5% to $1.18 during Thursday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 7.57% to $0.34. The company's market cap stands at $7.1 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock fell 7.41% to $0.5. The market value of their outstanding shares is at $4.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock declined by 5.03% to $1.7. The market value of their outstanding shares is at $2.3 million. </li>
<li>2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) stock fell 4.85% to $4.52. The company's market cap stands at $232.7 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares fell 4.52% to $1.69. The company's market cap stands at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIMD

AVGR

BBLG

CTCX

IPSC

OTLK

PHAT

RENB

ROIV

TOVX

TSVT

12 Health Care Stocks Moving In Thursday's After-Market Session

AIM ImmunoTech shares are trading higher after the company announced it was granted U.S. patent No. 12,102,649 for Ampligen for the treatment of endometriosis.

Legal

AIM ImmunoTech Granted U.S. Patent No. 12,102,649 For Ampligen For Treatment Of Endometriosis.

AIM ImmunoTech Inc. (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered direct offering at a purchase price of $0.27 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class C warrants to purchase up to an aggregate of 4,653,036 shares of common stock and, unregistered Class D warrants to purchase up to an aggregate of 4,653,036 shares of common stock. The Class C and Class D warrants will each have an exercise price of $0.28, will be exercisable six months from the date of issuance and, in the case of the Class C warrants, will expire on the eighteen-month anniversary from the initial exercise date, and in the case of the Class D warrants, will expire on the five-year anniversary from the initial exercise date. &nbsp;
The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $1.26 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company.
Maxim Group LLC is acting as the sole placement agent in connection with the offering.

Offerings

AIM ImmunoTech Announces Pricing Of $1.26M Registered Direct Offering Of 4,653,036 Shares Of Common Stock At A Purchase Price Of $0.27 Per Share

WIIM

AIM ImmunoTech shares are trading higher after the company announced preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi.

AIM ImmunoTech Announces Prelim. Data From Phase 1b/2 Study Of Ampligen And Imfinzi; Says 'Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort'

<a href="https://www.globenewswire.com/Tracker?data=gxQnjzLT-PgKGShQ5eS0a3RWpYoCUM7RzFGzykXV88Dh4mP14LGecYre1GS5QO79HBd6YdRqh-t1bSAt2UBjhhMzPq-RfSeUGJIcW93E1gE=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM") today announced that an analysis of the complete clinical patient data from the AMP-518 clinical trial supported the Company's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for AIM's planned follow-up clinical trial.

AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical Trial

Here's the major earnings before the open tomorrow

AIM ImmunoTech GAAP EPS of -$0.06

Reports Q3 revenue $35,000, consensus $11,670. AIM CEO Thomas Equels stated, "We are driving significant momentum across multiple clinical programs...

AIM ImmunoTech reports Q3 EPS (6c), consensus (9c)

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – AIM ImmunoTech (AIM) up 10% Nexxen (NEXN) up ...

Morning Movers: Spectrum Brands dips after fourth quarter earnings

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Shares of Domino's Pizza (DPZ) w...

Berkshire reveals stake in Domino's, Alibaba reports mixed Q2: Morning Buzz

16:37 EST AIM ImmunoTech (AIM) files to sell 9.31M shares of common stock for holders Published first on TheFly – the ultimate source for real-time...

AIM ImmunoTech files to sell 9.31M shares of common stock for holders

Aim Immunotech Inc. ( ($AIM) ) has released its Q3 earnings. Here is a breakdown of the information Aim Immunotech Inc. presented to its investors....

Aim Immunotech Reports Third Quarter Earnings

Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney iss...

Kellner Group urgers stockholders of AIM Immunotech to vote for nominees

AIM ImmunoTech (AIM) announced that data were published on Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating AIM ImmunoTech's dru...

AIM ImmunoTech announces data pubished on Part 1 study on Ampligen

ALHC

AMAT

AMZN

ASTS

CASI

DESP

HALO

OKLO

RCAT

SEDG

SLGL

SSNLF

TRUG

TWLO

Health Care

Press Releases

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

Comments

AIM ImmunoTech

Notizie

Ultime notizie per AIM ImmunoTech (AMEX:AIM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO